BNP Paribas Financial Markets
ALDX icon

BNP Paribas Financial Markets’s Aldeyra Therapeutics ALDX Stock Holding History

BNP Paribas Financial Markets’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.4K Sell
29,815
-233,592
-89% -$1.02M ﹤0.01% 4689
2025
Q4 		$1.36M Buy
263,407
+252,797
+2,383% +$1.3M ﹤0.01% 2895
2025
Q3 		$55.4K Buy
10,610
+2,859
+37% +$14.9K ﹤0.01% 4558
2025
Q2 		$29.7K Sell
7,751
-19,342
-71% -$50K ﹤0.01% 4448
2025
Q1 		$156K Buy
27,093
+20,738
+326% +$123K ﹤0.01% 3848
2024
Q4 		$31.7K Sell
6,355
-7,874
-55% -$40.4K ﹤0.01% 4586
2024
Q3 		$76.7K Buy
14,229
+10,201
+253% +$48.6K ﹤0.01% 3528
2024
Q2 		$13.3K Sell
4,028
-21,250
-84% -$83.2K ﹤0.01% 3696
2024
Q1 		$82.7K Buy
25,278
+4,797
+23% +$15.8K ﹤0.01% 3483
2023
Q4 		$71.9K Sell
20,481
-47,460
-70% -$146K ﹤0.01% 3478
2023
Q3 		$454K Buy
67,941
+8,122
+14% +$60.3K ﹤0.01% 2769
2023
Q2 		$502K Buy
+59,819
New +$589K ﹤0.01% 2579
2023
Q1 		– Sell
-53
Closed -$369 – 3852
2022
Q4 		$369 Sell
53
-593
-92% -$3.39K ﹤0.01% 3884
2022
Q3 		$3.45K Sell
646
-1,554
-71% -$9.32K ﹤0.01% 4289
2022
Q2 		$8.78K Sell
2,200
-5,268
-71% -$18.1K ﹤0.01% 3760
2022
Q1 		$33.2K Sell
7,468
-2,468
-25% -$9.83K ﹤0.01% 3639
2021
Q4 		$39.7K Buy
9,936
+1,272
+15% +$9.7K ﹤0.01% 3777
2021
Q3 		$76.1K Buy
8,664
+6,821
+370% +$62.6K ﹤0.01% 3385
2021
Q2 		$20.9K Sell
1,843
-30,049
-94% -$361K ﹤0.01% 3521
2021
Q1 		$379K Buy
+31,892
New +$367K ﹤0.01% 2729
2020
Q4 		– Sell
-1,257
Closed -$9.31K – 4144
2020
Q3 		$9.31K Sell
1,257
-36,326
-97% -$235K ﹤0.01% 3969
2020
Q2 		$157K Buy
37,583
+30,484
+429% +$111K ﹤0.01% 2587
2020
Q1 		$17.5K Buy
7,099
+3,287
+86% +$14.8K ﹤0.01% 3936
2019
Q4 		$22.1K Buy
3,812
+378
+11% +$2.18K ﹤0.01% 3968
2019
Q3 		$18.1K Buy
3,434
+856
+33% +$4.61K ﹤0.01% 3987
2019
Q2 		$15.5K Sell
2,578
-1,812
-41% -$13.6K ﹤0.01% 3988
2019
Q1 		$39.6K Buy
+4,390
New +$37.3K ﹤0.01% 3634
2018
Q4 		– Sell
-521
Closed -$7.19K – 4332
2018
Q3 		$7.19K Hold
521
– – ﹤0.01% 3897
2018
Q2 		$4.14K Buy
+521
New +$4.16K ﹤0.01% 4147

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BNP Paribas Financial Markets's ALDX Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its Aldeyra Therapeutics (ALDX) stake by 89% in Q1 2026, selling an estimated $1.02M and leaving 29,815 shares worth $50.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4689.

BNP Paribas Financial Markets first reported a position in ALDX in Q2 2018 and has held it in 29 quarters since. The position peaked at $1.36M in Q4 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • BNP Paribas Financial Markets held 29,815 shares of Aldeyra Therapeutics worth $50.4K as of Q1 2026.
  • BNP Paribas Financial Markets sold 233,592 Aldeyra Therapeutics shares in Q1 2026, an estimated $1.02M.
  • Aldeyra Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4689 holding.
  • BNP Paribas Financial Markets first reported a position in Aldeyra Therapeutics in Q2 2018 and has held it in 29 quarters since.
  • BNP Paribas Financial Markets's Aldeyra Therapeutics position peaked at $1.36M in Q4 2025.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.